Abstract

Dindayal Darunde*, Sandip Umare, Jija Lode, Amol Badkhal, Priti Chincholkar and Bharti Dhole

ABSTRACT

Malaria is a devastating disease that has plagued humanity for millennia. Despite accumulating circumstantial evidence suggesting a link between mosquitoes and malaria transmission, ancient civilizations did not comprehend the role of the parasite in spreading the disease. The development of a malaria vaccine has been a persistent challenge due to the complex nature of the malaria parasite and its ability to evade the immune system. Among the various malaria vaccine candidates undergoing clinical trials, the RTS, S vaccine has emerged as a frontrunner, having progressed from trials to implementation due to its promising results in reducing both clinical and severe cases of malaria. The complexity of developing a cost-effective vaccine against malaria, particularly in areas with moderate to high transmission rates, adds another layer of difficulty to the already challenging landscape of malaria vaccine development.